50.Issue 05 may 23 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 10, Issue : 05, May – 2023

Title:

50.A SYSTEMATIC META‑ANALYSIS OF COMPARISON OF THE CLINICAL EFFICACY OF COVID‑19 VACCINES
‬

Authors :

Hadiya Rahman.

Abstract :

COVID‑19) vaccines are available to prevent the ongoing severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) pandemic. We compared the efficacy of new COVID‑19 vaccines to prevent symptomatic and severe disease in the adult population and to prevent symptomatic COVID‑19 among the elderly. Leading medical databases were searched until August 30, 2021. Published phase 3 randomized controlled trials (RCTs) evaluated efficacy of the vaccine to prevent symptomatic and sever COVID‑19 in adults were included. Two reviewers independently evaluated the literature search results and independently extracted summary data. The risk of bias was evaluated using the Cochrane Risk of Bias Assessment Tool.
In our indirect comparison, the BNT162b2 and mRNA-1273 vaccines, which use mRNA technology, were associated with the highest efficacy in preventing symptomatic COVID-19 compared to the other vaccines. The compared vaccines were not different in efficacy to prevent severe disease. We found no difference between vaccines’ efficacy to prevent symptomatic COVID-19 among the elderly.

Cite This Article:

Please cite this article in press Hadiya Rahman et al, A Systematic Meta‑Analysis Of Comparison Of The Clinical Efficacy Of Covid‑19 Vaccines., Indo Am. J. P. Sci, 2023; 10 (05).

Number of Downloads : 10

References:

1. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
2. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https:// covid 19. who. int/.
3. Vaccine Development, Testing, and Regulation | History of Vaccines. https:// www. histo ryofv accin es. org/ conte nt/ artic les/ vacci ne- devel opment- testi ng- and- regul ation.
4. Papageorgiou, A. C. & Mohsin, I. The SARS-CoV-2 spike glycoprotein as a drug and vaccine target: structural insights into its complexes with ACE2 and antibodies. Cells 9, 2 (2020).
5. COVID-19 vaccine tracker and landscape. https://w ww.who.i nt /public ati ons/m/i tem /draft-l and scape-o f -covid-1 9 -candid ate -vacci nes.
6. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
7. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
8. Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881 (2021).
9. Sadoff, J. et al. Safety and efficacy of single-dose Ad2.6COV2.S vaccine against COVID-19. N. Engl. J. Med. https://d oi.org/1 0 .1056 / NEJMo a2101 544 (2021).
10. Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671–681 (2021).
11. Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. https:// doi. org/ 10. 1056/ NEJMO A2107 659 (2021).
12. Awadasseid, A., Wu, Y., Tanaka, Y. & Zhang, W. Current advances in the development of SARS-CoV-2 vaccines. Int. J. Biol. Sci.2021, 8–19 (2021).
13. Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).
14. Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).
15. Xu, S., Yang, K., Li, R. & Zhang, L. Molecular sciences mRNA vaccine era-mechanisms, drug platform and clinical prospection.doi:https:// doi. org/ 10. 3390/ ijms2 11865 82.
16. Angel, Y. et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA – J. Am. Med. Assoc. https:// doi. org/ 10. 1001/ jama. 2021. 7152 (2021).
17. Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819–1829 (2021).
18. Hall, V. J. et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 397, 1725–1735 (2021).
19. Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. https://d oi.org/1 0 . 1056/ NEJMo a2101 765 (2021).
20. Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ https:// doi. org/ 10. 1136/ bmj. n1088 (2021).
21. Keech, C. et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320–2332 (2020).
22. Vaccine against Ebola. https:// ec. europa. eu/ commi ssion/ press corner/ detail/ en/ ip_ 20_ 1248.
23. Wold, W. & Toth, K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr. Gene Ther. 13, 421–433 (2014).
24. Al Kaabi, N. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA https:// doi. org/ 10. 1001/ jama. 2021. 8565 (2021).
25. Tanriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398, 213–222 (2021).
26. H, C. et al. Efficacy and safety of COVID-19 vaccines in phase III trials: a meta-analysis. Vaccines 9, 2 (2021).
27. Rouse, B., Chaimani, A. & Li, T. Network meta-analysis: an introduction for clinicians. Intern. Emerg. Med. 12, 2 (2021).
28. Calzetta, L. et al. Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials. Vaccines 9, 341 (2021).
29. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Systematic reviews and meta-analyses CHECK LIST: The PRISMA statement. PLoS Med 6, e1000097 (2009).
30. Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 5, 1–10 (2016).
31. Higgins, J. P. T. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, 2 (2011).
32. Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162, 777–784 (2015).
33. Gorelik, E. et al. Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrob. Agents Chemother. 62, 2 (2018).
34. Gorelik, E. et al. Fluoroquinolones and cardiovascular risk: a systematic review Meta-analysis and Network Meta-analysis. Drug Saf. 42, 2 (2019).
35. Leshem, R. et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) during pregnancy and the risk for autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in the offspring: A true effect o. Curr. Neuropharmacol. 19, 896–906 (2021).
36. R, M. et al. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. Am. J. Obstet. Gynecol. 220, 57–57 (2019).
37. Rücker, G. & Schwarzer, G. Ranking treatments in frequentist network meta-analysis works without resampling methods. Med. Res. Methodol. 15, 58 (2015).
38. Package ‘netmeta’ Title Network Meta-Analysis using Frequentist Methods. (2021) doi:https://d oi.org/1 0 .1007/9 78-3 -319-2 141 6.
39. Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 396, 1979–1993 (2020).
40. Bos, R. et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 5, 1–11 (2020).
41. Janssen Vaccines & Prevention B.V. A Study of Ad26.COV2.S in Adults (COVID-19). https:// www. clini caltr ials. gov/ ct2/ show/NCT***04436276 (2020).
42. Lu, S. Heterologous prime-boost vaccination. doi:https:// doi. org/ 10. 1016/j. coi. 2009. 05. 016.
43. Novavax COVID-19 Vaccine Demonstrates 89 . 3 % Efficacy in UK Phase 3 Trial. (2021).
44. Biotech, J. Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Briefing Document- FDA. (2021).
45. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. www. thela ncet. com 397, 2021 (2020).
46. Xie, X. et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Biorxiv Prepr Serv. Biol. https:// doi. org/ 10. 1101/ 2021. 01. 07. 425740 (2021).
47. Wu, K. et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv Prepr. Serv. Biol. 2021.01.25.427948 (2021) doi:https:// doi. org/ 10. 1101/ 2021. 01. 25. 427948.
48. Noa, D. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. https:// doi. org/ 10. 1056/ NEJMo a2101 765 (2021).